Treatment of Sjögren Syndrome with Cryoglobulinemic Membranoproliferative Glomerulonephritis
This protocol applies to patients with Sjögren syndrome who present with
cryoglobulinemic membranoproliferative glomerulonephritis,
positive serum cryoglobulins, and active systemic disease — a constellation requiring a
severity-stratified treatment approach.
Clinical Scenario
The presence of cryoglobulinemic membranoproliferative glomerulonephritis and
positive serum cryoglobulins alongside active systemic Sjögren syndrome defines
a high-complexity subset. Treatment of the systemic disease must be tailored to organ-specific
severity using the ESSDAI definitions.
The best indication for this treatment pathway is probably for symptoms linked to
cryoglobulinemic-associated vasculitis.
Treatment Approach (partial overview)
The structured regimen centres on glucocorticoid therapy, with the specific
approach — including whether oral or intravenous induction is used — determined by the severity
of presentation. The full sequencing, dosing strategy, and criteria for escalation or tapering
are detailed in the complete protocol.
Complete regimen, dose guidance, and algorithm available via the link below.
▶
Treatment goal: A reduction of ≥3 points in the global ESSDAI score is the
recommended benchmark for defining a meaningful therapeutic response in systemic Sjögren syndrome.
References
DOI: 10.1136/annrheumdis-2019-216114
- Treatment of systemic disease should be tailored to organ-specific severity using the ESSDAI definitions.
- The best indication is probably for symptoms linked to cryoglobulinemic-associated vasculitis.
- GCs should be used at the minimum dose and length of time necessary to control active systemic disease, administering pulses of methylprednisolone followed by doses of 0.5 mg/kg/d or lower as induction therapy in severe presentations, and doses <0.5 mg/kg/d in moderate/less-severe presentations, with a final target of withdrawing GCs in inactive patients as soon as possible or at least trying to target a maintenance dose of 5 mg/daily or less with the aid of GC-sparing immunosuppressive agents.
- With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of ≥3 points in the global ESSDAI score.
View source ↗